[Extracorporeal shockwave therapy in symptomatic heel spurs. An overview].

Abstract

Extracorporeal shock wave application (ESWA) has been successfully used for years in routine clinical management of plantar fasciitis. So far no clinical trails have shown the efficiency in placebo-controlled protocols. This paper presents an overview of conservative and operative treatment modalities with respect to their efficacy. Results of a prospective randomized placebo-controlled double-blind multicenter trial to show efficiency and safety of ESWT are presented. In patients treated conservatively without success, a single shock wave application can improve the condition significantly compared with placebo treatment (p = 0.0149). The Roles and Maudsley score also showed a significant improvement between the groups, with 61.6% good or excellent results in the verum group and 39.7% in the placebo group (p = 0.0128). Therapy-related side effects (local swelling, petechia) are rare. The data presented in this study led to FDA approval in January 2002 of the shock wave device used.

• Authors: M Buch, U Knorr, L Fleming, G Theodore, A Amendola, C Bachmann, C Zingas, W E Siebert
• Journal: Der Orthopade (Orthopade) Vol. 31 Issue 7 Pg. 637-44 (Jul 2002) ISSN: 0085-4530 [Print] Germany
• Vernacular Title: Extrakorporale Stosswellentherapie beim symptomatischen Fersensporn. Eine Ubersicht.
• PMID: 12219661 (Publication Type: Clinical Trial, Evaluation Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Topics

• Adult
• Aged
• Double-Blind Method
• Fasciitis, Plantar (therapy)
• Female
• Heel Spur (therapy)
• Humans
• Lithotripsy
• Male
• Middle Aged
• Pain Measurement
• Treatment Outcome